Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | Addressing unmet clinical needs with the CD8 ImmunoPET minibody

Ian A. Wilson • 12 Nov 2021
SITC 2021
General Antibodies

Ian A. Wilson, PhD, ImaginAb Inc., Los Angeles, CA, explains how the CD8 ImmunoPET minibody addresses important unmet clinical needs. Specifically highlighted is how this technology can be used to accurately and quickly monitor responses to immunotherapy. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

More from Ian A. Wilson

0:41
Next steps for the CD8 ImmunoPET minibody
Ian A. Wilson • 12 Nov 2021
1:03
Latest developments in radiopharmaceutical therapies
Ian A. Wilson • 12 Nov 2021

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals